Philippe Busque - Cytek Biosciences Senior Services
| CTKB Stock | USD 6.30 0.10 1.61% |
Executive
Philippe Busque is Senior Services of Cytek Biosciences
| Address | 47215 Lakeview Boulevard, Fremont, CA, United States, 94538 |
| Phone | 877 922 9835 |
| Web | https://cytekbio.com |
Cytek Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.0306) % which means that it has lost $0.0306 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0282) %, meaning that it created substantial loss on money invested by shareholders. Cytek Biosciences' management efficiency ratios could be used to measure how well Cytek Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of May 11, 2024, Return On Tangible Assets is expected to decline to -0.03. The current year's Return On Capital Employed is expected to grow to -0.06. At present, Cytek Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 110.9 M, whereas Total Assets are forecasted to decline to about 389.7 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chris Tyson | Monogram Orthopaedics Common | N/A | |
| Angela Ahmad | Inari MedicalInc | N/A | |
| Michael Brown | DexCom Inc | 54 | |
| Leverne Marsh | DexCom Inc | N/A | |
| Mark Wilterding | Edwards Lifesciences Corp | N/A | |
| Jane Rady | Glaukos Corp | 76 | |
| Gary Sorsher | Edwards Lifesciences Corp | 59 | |
| Arnold Pinkston | Edwards Lifesciences Corp | 65 | |
| Finn Haley | Edwards Lifesciences Corp | N/A | |
| Kevin Strange | Inari MedicalInc | N/A | |
| Christopher Lewis | Glaukos Corp | N/A | |
| Christine McCauley | Edwards Lifesciences Corp | 59 | |
| MD FACC | Edwards Lifesciences Corp | N/A | |
| John Borrell | Inari MedicalInc | 57 | |
| Matthew Dolan | DexCom Inc | 43 | |
| Scott Leinenweber | Abbott Laboratories | 52 | |
| Sadie Stern | DexCom Inc | 49 | |
| Michele Allegretto | Glaukos Corp | N/A | |
| John Soto | Butterfly Network | 60 | |
| Shelly Selvaraj | DexCom Inc | 65 | |
| Brian Strauss | Inari MedicalInc | N/A | |
Management Performance
| Return On Equity | -0.0282 | ||||
| Return On Asset | -0.0306 |
Cytek Biosciences Leadership Team
Elected by the shareholders, the Cytek Biosciences' board of directors comprises two types of representatives: Cytek Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytek. The board's role is to monitor Cytek Biosciences' management team and ensure that shareholders' interests are well served. Cytek Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytek Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wenbin Jiang, CEO President | ||
| Todd Garland, Chief Officer | ||
| Ming Yan, CTO Director | ||
| Melik Ulusu, Senior Chain | ||
| Mark Edinger, VP Affairs | ||
| Allen Poirson, Senior Development | ||
| Connie Wedel, Chief Officer | ||
| Chris Williams, Chief Officer | ||
| Paul Goodson, Head Relations | ||
| William McCombe, Chief Officer | ||
| Philippe Busque, Senior Services | ||
| Patrik Jeanmonod, Head Analytics | ||
| Valerie JD, General Secretary |
Cytek Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cytek Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0282 | ||||
| Return On Asset | -0.0306 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 553.86 M | ||||
| Shares Outstanding | 131.27 M | ||||
| Shares Owned By Insiders | 8.70 % | ||||
| Shares Owned By Institutions | 65.10 % | ||||
| Number Of Shares Shorted | 7.85 M | ||||
| Price To Book | 2.13 X |
Pair Trading with Cytek Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytek Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytek Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Cytek Stock
| 0.66 | NRC | National Research Corp | PairCorr |
| 0.62 | HSTM | HealthStream | PairCorr |
| 0.83 | MASS | 908 Devices Financial Report 14th of May 2024 | PairCorr |
Moving against Cytek Stock
| 0.71 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.61 | ERNA | Eterna Therapeutics | PairCorr |
| 0.47 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
| 0.42 | FBRX | Forte Biosciences Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Cytek Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytek Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytek Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytek Biosciences to buy it.
The correlation of Cytek Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytek Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytek Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytek Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Cytek Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.658 | Earnings Share (0.09) | Revenue Per Share 1.497 | Quarterly Revenue Growth 0.21 | Return On Assets (0.03) |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.